Pellegrini: A Retrospective Analysis of Outcomes Amongst COVID-19 Infected Patients with Acute Hepatitis Receiving N-Acetylcysteine Therapy in a Safety Net Hospital

A Retrospective Analysis of Outcomes Amongst COVID-19 Infected Patients with Acute Hepatitis Receiving N-Acetylcysteine Therapy in a Safety Net Hospital

Pellegrini et al., Gastroenterology, doi:10.1016/S0016-5085(21)02756-6

Pellegrini et al., A Retrospective Analysis of Outcomes Amongst COVID-19 Infected Patients with Acute Hepatitis Receiving.., Gastroenterology, doi:10.1016/S0016-5085(21)02756-6

May 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 864 hospitalized late stage COVID-19 patients in the USA, 138 receiving NAC treatment for acute hepatitis, showing lower mortality with treatment. Results are adjusted for confounders, however details are not provided.

Important missing comments or errors? Let us know.

risk of death, 51.7% lower, OR 0.48, p < 0.001, treatment 138, control 726, adjusted per study, inverted to make OR<1 favor treatment, multivariable, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Pellegrini et al., 23 May 2021, retrospective, USA, peer-reviewed, 10 authors, study period March 2020 - May 2020.

All Studies All Outcomes Submit Updates or Corrections

This Paper N-acetylcys..All

Abstract: Powered by TCPDF (www.tcpdf.org)

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit